NCT04060654View on ClinicalTrials.gov

SUBLOCADE Rapid Initiation Extension Study

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 21, 2019

Primary Completion Date

May 15, 2020

Study Completion Date

May 15, 2020

Conditions
Opioid Use Disorder, SevereOpioid Use Disorder, Moderate
Interventions
DRUG

Sublocade

SUBLOCADE to be administered approximately every 4 weeks per local standard of care

Trial Locations (1)

08009

Hassman Research Institute, Berlin

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT04060654 - SUBLOCADE Rapid Initiation Extension Study | Biotech Hunter | Biotech Hunter